| Bioactivity | SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC50s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion. SIAIS039 suppresses cell proliferation, induces cell cycle arrest, and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker)[1]. |
| CAS | 2570251-69-1 |
| Formula | C46H53ClN9O5P |
| Molar Mass | 878.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiawen Yang, et al. Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1). Bioorg Chem. 2024 Sep:150:107590. |
SIAIS039
CAS: 2570251-69-1 F: C46H53ClN9O5P W: 878.40
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC50s of 154.46nM, 126.47nM, 143.69nM for HCC7
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.